Autonomous Analytical Development
for Drug Makers.
A software-defined laboratory platform delivering regulatory-grade CMC documentation in 7 days. Powered by multi-agent AI and cloud robotics.
CMC is the last bottleneck
in drug development.
AI has transformed drug discovery — but downstream analytical method development and validation remains a manual, labor-intensive process. The cost is measured in months, dollars, and missed patient access.
From
to a validated assay.
A continuous, autonomous loop replaces the traditional 4–8 month analytical development cycle. Four phases. One week. Submission-ready output.
In Silico Design
Thermodynamic simulation & reagent procurement
Robotic Execution
Sample barcoding & automated inventory mapping
Closed-Loop Optimization
Real-time AI feedback & adaptive DoE
Compliance Output
Auto-generated eCTD Module 3.2.P.5 with audit trail
Five specialized agents.
One autonomous system.
ADevGalaxy replaces the traditional analytical development department with a constellation of AI agents — each strictly bounded by a scientific responsibility, orchestrated end-to-end.
Orchestrator
Digital Head of Analytical Development
Ingests the Analytical Target Profile and routes work across the agent stack.
Bio-Architect
Computational Molecular Biologist
Predicts structures and optimal conditions in silico before reagents are consumed.
Lab Operative
Robotic Execution Layer
Translates designs into protocols and controls cloud robotics with sub-microliter precision.
Signal Analyst
Real-Time Data Intelligence
Deconvolves fluorescence signals live and triggers experimental matrix revisions.
Compliance Agent
Regulatory Brain
Captures cryptographically hashed audit trails and drafts FDA/EMA validation dossiers.
Founded at the intersection of
molecular biology and agentic AI.
A bilingual founding team — fluent in both wet-lab science and AI architecture — codifying a rare confluence of skills into the ADevGalaxy platform.
Talk to ADevGalaxy about your
first autonomous assay.
We're actively onboarding pilot partners and speaking with seed-stage investors. Book a 30-minute intro or send a note — we read every email.